Back to top
Clinical stage:
In-vitro formulation

N4 Pharma has filed a patent for the reformulation of anti-depressant drug, duloxetine, for the treatment of premature ejaculation. This product differs slightly to N4 Pharma’s standard approach in that, although duloxetine has been researched to show its efficacy for premature ejaculation , no clinical trials have been performed to date since there is no patent protection for the generic drug. N4 Pharma’s reformulation will provide patent protection, thereby allowing a partner to undertake the required trials knowing that the final product will be commercially protected. Premature ejaculation is believed to affect up to 30 per cent of American males, equivalent to approximately 20 million adults per year.